Drug Science is pleased to welcome Grow Pharma as a partner on its groundbreaking medical cannabis study, T21.
Launched in 2019, T21 is building a strong evidence base for the safety and efficacy of cannabis medicines, ultimately increasing UK patients’ access to them on the NHS.
The project does this by allowing registered UK patients to access discounted private prescriptions of these legal medicines, which are provided by industry partners Khiron Life Sciences Corp, Leva, JMCC Group, Canopy Growth (under the Spectrum Therapeutical brand) and Ethypharm.
And by joining T21’s partners, Grow Pharma will help to ensure the future of the project, allowing patients to continue with their discounted medications, and for scientists to collect important health data on these drugs and their effects.
Grow Pharma also allows T21 to extend its formulary — by adding more cannabis-based medicines and offering more choice to the study’s patients.
Pierre van Weperen is the Chief Executive of Grow Pharma. He says:
“We are proud to be joining T21. Our involvement is testament to our mission of making quality cannabis medicines affordable for UK patients. We have been considering joining for some time and with some of the changes that have been made we feel the time is right. We look forward to working with Drug Science and with the clinics and producers involved in the study.”
David Badcock is the Chief Executive of Drug Science. He says:
“We’re very happy that Grow Pharma has joined T21 and that they, and our existing partners, are allowing UK patients to access discounted prescriptions. We already know that these drugs can benefit a wide range of conditions – from childhood epilepsy to chronic pain and PTSD. And as our study grows stronger, the closer we will get to widening public access to these important, life-changing medications.’
For more information please contact email@example.com